<DOC>
	<DOCNO>NCT03075267</DOCNO>
	<brief_summary>A study ass pharmacokinetics safety two dos PT010 single dose PT003 healthy Chinese adult subject</brief_summary>
	<brief_title>Phase I Study Assess Pharmacokinetics Safety Two Doses PT010 Single Dose PT003 Healthy Chinese Adult Subjects Following A Single Administration After Chronic Administration 7 Days</brief_title>
	<detailed_description>A Phase I , Randomized , Double-Blind , Parallel Group , Study Assess Pharmacokinetics Safety Two Doses PT010 Single Dose PT003 Healthy Chinese Adult Subjects Following Single Administration After Chronic Administration 7 Days</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Male female Chinese subject 1845 year age Females childbearing potential must agree abstinent else use one follow medically acceptable form contraception A female whose male partner vasectomy must agree use one additional form medically acceptable contraception . A male subject female partner child bear potential must agree use one additional form medically acceptable contraception Be good general health assess Screening clinically significant abnormal lab Screening . Pregnant nursing female subject subject try conceive Subjects clinically significant neurologic , cardiovascular , hepatic , renal , endocrinologic , pulmonary , hematological , psychiatric , medical illness would interfere participation study ; Subjects history ECG abnormalities Subjects cancer complete remission least 5 year ; Male subject symptomatic prostatic hypertrophy clinically significant opinion Investigator ; Male subject transurethral resection prostate full resection prostate within 6 month prior Screening ; Males bladder neck obstruction urinary retention clinically significant opinion Investigator ; Subjects diagnosis glaucoma opinion Investigator adequately treat ; History substancerelated disorder within 1 year Screening ; History smoking use nicotine contain product electronic cigarette within 3 month Screening selfreporting ; A positive alcohol breathalyzer urine drug screen drug abuse Screening Visit begin inpatient period ; Treatment prescription nonprescription drug ( include vitamin , herbal , dietary supplement ) within 30 day Positivity human immunodeficiency virus ( HIV ) Hepatitis B surface antigen ( HbsAg ) positive hepatitis C antibody Screening Positive Syphilis Antibody Subjects flulike syndrome respiratory infection Recently vaccinate attenuated live virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>